Zobrazeno 1 - 10
of 78
pro vyhledávání: '"William E Janssen"'
Autor:
David Cullins, Barbara Rooney, Natasha Sahr, April Sykes, Mary Beth McCarville, Sara M Federico, Amanda Sooter, William E Janssen, Gwendolyn Anthony, Michael A Dyer, Alberto S Pappo, Wing H Leung, Wayne L Furman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundNatural killer (NK) cells are one of the main effector populations of immunotherapy with monoclonal antibody and cytokines, used in combination with chemotherapy to treat children with high-risk neuroblastoma on this phase II trial. However
Externí odkaz:
https://doaj.org/article/61aa4de3291f4f04b11f55638ec3891c
Autor:
Rosa Nguyen, Huiyun Wu, Stanley Pounds, Hiroto Inaba, Raul C. Ribeiro, David Cullins, Barbara Rooney, Teresa Bell, Norman J. Lacayo, Kenneth Heym, Barbara Degar, Deborah Schiff, William E. Janssen, Brandon Triplett, Ching-Hon Pui, Wing Leung, Jeffrey E. Rubnitz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if adoptive transfer of natural kille
Externí odkaz:
https://doaj.org/article/4196b54e9163489ba534ba9dc6b66a38
Autor:
William E Janssen, Scott R. Burger
Publikováno v:
Cell and Gene Therapy Insights. :1375-1379
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
This figure demonstrates the relationship between prior treatment with chimeric or humanized 14.18 K322A antibody and A) the area under the concentration curve for the antibody (AUC); B elimination half-life of the antibody (T1/2 Beta); and C) the hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dda4536ff96c433e250a2f403355bb7
https://doi.org/10.1158/1078-0432.22468175.v1
https://doi.org/10.1158/1078-0432.22468175.v1
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Box and whisker plot showing absolute NK cells per mm3 in samples. NK cells were identified by flow cytometry as CD14 negative, CD56 positive, CD3 negative and percentage of total WBC was computed from flow cytometry results. Absolute WBC count was o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62a93dddc4f296d3df3b810cfbce1b0
https://doi.org/10.1158/1078-0432.22468169.v1
https://doi.org/10.1158/1078-0432.22468169.v1
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Human anti-human antibody (HAHA) level and peak hu14.18K322A serum level by course and prior antibody therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120d7121dd373ab23a3e06c8088d7313
https://doi.org/10.1158/1078-0432.22468163
https://doi.org/10.1158/1078-0432.22468163
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7234f9e79e0bc385c497d16381d6d10f
https://doi.org/10.1158/1078-0432.c.6526859.v1
https://doi.org/10.1158/1078-0432.c.6526859.v1
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
The left panel plots the calculated area under the concentration vs time curve (AUC) of hu14.18K322A and the right panel plots the highest observed serum concentration of hu14.18K322A (Cmax) against the pre-treatment concentration of HAHA antibodies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cf4fb5f2122705d1133af93245a8ae
https://doi.org/10.1158/1078-0432.22468172
https://doi.org/10.1158/1078-0432.22468172
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Plot of ADCC assay reports comparing 6 lots of hu14.18K322A in comparison to dinutuximab (unituxin). M21 cells, expressing the GD2 cell surface epitope, served as the target cells. Engineered Jurkat cells, with a cell-surface FcyRIIIa (V158) receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bae9f45962e4b948830f33d6f895823f
https://doi.org/10.1158/1078-0432.22468178
https://doi.org/10.1158/1078-0432.22468178
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Individual pharmacokinetic parameters in 3 subpopulations (no prior 14.18 mAb, prior dinutuximab mAb, prior hu14.18K322A mAb).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d6536010dca5a082d1a3ab6094a3eba
https://doi.org/10.1158/1078-0432.22468166.v1
https://doi.org/10.1158/1078-0432.22468166.v1